Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.

Am J Hum GenetSep 3, 2026 (epub)
Clinical ResearchHematologyNephrologyPulmonologyInternal Medicine (General)Open access

Micah R Hysong, Megan M Shuey, Tyne W Miller-Fleming et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the health outcomes associated with sickle cell trait (SCT) in 4,813 individuals of African genetic ancestry. The study confirmed significant associations between SCT and increased risks of kidney disease, pulmonary embolism, and anemia, among others. The findings were supported by data from three large US biobanks and a published PheWAS from the Million Veteran Program.

Key findings

  • SCT is associated with increased risks of kidney disease, pulmonary embolism, and anemia.
  • Higher serum electrolytes, bilirubin, and reticulocyte count were found in individuals with SCT.
  • The association of SCT with kidney-related disorders was stronger in females.
  • Males with SCT showed greater associations with platelet and lymphocyte phenotypes.

Why it matters

Understanding the multi-system complications associated with SCT can enhance clinical awareness and inform the interpretation of laboratory results. This knowledge is crucial for managing patients with SCT and addressing their specific health risks.

Source

PubMed · PMID 42692015Free full text on PubMed Central

Published in Am J Hum Genet. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.